Drug Treatment of COVID-19 Infection

Overview

Journal Curr Opin Pulm Med

Specialty Pulmonary Medicine

Date 2023 Mar 14

PMID 36917228

Authors

Grace Lui

Giovanni Guaraldi

Affiliations

Soon will be listed here.

Abstract

Purpose Of Review: COVID-19 pandemic has caused more than 6.6 million deaths globally. Tremendous efforts have been committed for the development of new and repurposed drugs for the treatment of COVID-19. Although different international and national guidelines share consensus in the management of COVID-19 disease with different levels of severity, new challenges have emerged, steering the need for ongoing research in advancing the clinical management of COVID-19.

Recent Findings: This review focuses on recent data from randomized trials and postmarketing real-world evidence for the treatment of mild to moderate disease in the outpatient setting and patients hospitalized for COVID-19 with varying level of severity. Relevant data for treatment of the latest omicron sub-variants in people who received vaccination are presented. Challenges in special populations, including immunocompromised hosts, patients with renal failure and pregnant women, are also discussed.

Summary: Treatment of COVID-19 should be personalized according to host characteristics, degree of severity and available treatment options.

Citing Articles

Adjuvants to the S1-subunit of the SARS-CoV-2 spike protein vaccine improve antibody and T cell responses and surrogate neutralization in mice.

Becker W, Rebbani K, Duan Z, Valkov E, Bryant S, Ho M Sci Rep. 2024; 14(1):29609.

PMID: 39609527 PMC: 11604653. DOI: 10.1038/s41598-024-80636-3.

In Silico Evaluation of HIV Protease and RNA Polymerase Inhibitors as Potential COVID-19 Therapeutics.

Devaraji M, Ravikumar L Cureus. 2024; 16(9):e69576.

PMID: 39421085 PMC: 11483341. DOI: 10.7759/cureus.69576.

Management of patients with neurological diseases considering post-pandemic coronavirus disease 2019 (COVID-19) related risks and dangers - An updated European Academy of Neurology consensus statement.

Filipovic S, Ozturk S, Bereczki D, Bodini B, Cavallieri F, Fanciulli A Eur J Neurol. 2024; 31(10):e16408.

PMID: 39088330 PMC: 11414794. DOI: 10.1111/ene.16408.

A Dynamic and Effective Peptide-Based Strategy for Promptly Addressing Emerging SARS-CoV-2 Variants of Concern.

Murdocca M, Romeo I, Citro G, Latini A, Centofanti F, Bugatti A Pharmaceuticals (Basel). 2024; 17(7).

PMID: 39065742 PMC: 11279616. DOI: 10.3390/ph17070891.

Safety of High-Dose Vitamin C in Non-Intensive Care Hospitalized Patients with COVID-19: An Open-Label Clinical Study.

Corrao S, Raspanti M, Agugliaro F, Gervasi F, Di Bernardo F, Natoli G J Clin Med. 2024; 13(13).

PMID: 38999551 PMC: 11242388. DOI: 10.3390/jcm13133987.

References

Wynia M, Beaty L, Bennett T, Carlson N, Davis C, Kwan B . Real-World Evidence of Neutralizing Monoclonal Antibodies for Preventing Hospitalization and Mortality in COVID-19 Outpatients. Chest. 2022; 163(5):1061-1070. PMC: 9613796. DOI: 10.1016/j.chest.2022.10.020. View

Gutierrez R, Mendez-Figueroa H, Biebighauser J, Bhalwal A, Pineles B, Chauhan S . Remdesivir use in pregnancy during the SARS-CoV-2 pandemic. J Matern Fetal Neonatal Med. 2022; 35(25):9445-9451. DOI: 10.1080/14767058.2022.2041595. View

Diaz G, Christensen A, Pusch T, Goulet D, Chang S, Grunkemeier G . Remdesivir and Mortality in Patients With Coronavirus Disease 2019. Clin Infect Dis. 2021; 74(10):1812-1820. PMC: 9155603. DOI: 10.1093/cid/ciab698. View

Wong G, Yip T, Lai M, Wong V, Hui D, Lui G . Incidence of Viral Rebound After Treatment With Nirmatrelvir-Ritonavir and Molnupiravir. JAMA Netw Open. 2022; 5(12):e2245086. PMC: 9856258. DOI: 10.1001/jamanetworkopen.2022.45086. View

Puhach O, Meyer B, Eckerle I . SARS-CoV-2 viral load and shedding kinetics. Nat Rev Microbiol. 2022; 21(3):147-161. PMC: 9716513. DOI: 10.1038/s41579-022-00822-w. View

Dioverti V, Salto-Alejandre S, Haidar G . Immunocompromised Patients with Protracted COVID-19: a Review of "Long Persisters". Curr Transplant Rep. 2022; 9(4):209-218. PMC: 9660019. DOI: 10.1007/s40472-022-00385-y. View

Martinez M, Chen T, Choi H, Hwang M, Navarathna D, Hao L . Extended Remdesivir Infusion for Persistent Coronavirus Disease 2019 Infection. Open Forum Infect Dis. 2022; 9(8):ofac382. PMC: 9384609. DOI: 10.1093/ofid/ofac382. View

Seethapathy R, Zhao S, Long J, Strohbehn I, Sise M . A Propensity Score-Matched Observational Study of Remdesivir in Patients with COVID-19 and Severe Kidney Disease. Kidney360. 2022; 3(2):269-278. PMC: 8967642. DOI: 10.34067/KID.0006152021. View

Horby P, Lim W, Emberson J, Mafham M, Bell J, Linsell L . Dexamethasone in Hospitalized Patients with Covid-19. N Engl J Med. 2020; 384(8):693-704. PMC: 7383595. DOI: 10.1056/NEJMoa2021436. View

10.

Anderson A, Caubel P, Rusnak J . Nirmatrelvir-Ritonavir and Viral Load Rebound in Covid-19. N Engl J Med. 2022; 387(11):1047-1049. PMC: 9513855. DOI: 10.1056/NEJMc2205944. View

11.

Epling B, Rocco J, Boswell K, Laidlaw E, Galindo F, Kellogg A . Clinical, Virologic, and Immunologic Evaluation of Symptomatic Coronavirus Disease 2019 Rebound Following Nirmatrelvir/Ritonavir Treatment. Clin Infect Dis. 2022; 76(4):573-581. PMC: 9619622. DOI: 10.1093/cid/ciac663. View

12.

Razonable R, OHoro J, Hanson S, Arndt R, Speicher L, Seville T . Comparable Outcomes for Bebtelovimab and Ritonavir-Boosted Nirmatrelvir Treatment in High-Risk Patients With Coronavirus Disease-2019 During Severe Acute Respiratory Syndrome Coronavirus 2 BA.2 Omicron Epoch. J Infect Dis. 2022; 226(10):1683-1687. PMC: 9494486. DOI: 10.1093/infdis/jiac346. View

13.

Valsecchi C, Winterton D, Safaee Fakhr B, Collier A, Nozari A, Ortoleva J . High-Dose Inhaled Nitric Oxide for the Treatment of Spontaneously Breathing Pregnant Patients With Severe Coronavirus Disease 2019 (COVID-19) Pneumonia. Obstet Gynecol. 2022; 140(2):195-203. PMC: 9994457. DOI: 10.1097/AOG.0000000000004847. View

14.

Lim S, Tignanelli C, Hoertel N, Boulware D, Usher M . Prevalence of Medical Contraindications to Nirmatrelvir/Ritonavir in a Cohort of Hospitalized and Nonhospitalized Patients With COVID-19. Open Forum Infect Dis. 2022; 9(8):ofac389. PMC: 9384640. DOI: 10.1093/ofid/ofac389. View

15.

Gupta A, Gonzalez-Rojas Y, Juarez E, Crespo Casal M, Moya J, Falci D . Effect of Sotrovimab on Hospitalization or Death Among High-risk Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial. JAMA. 2022; 327(13):1236-1246. PMC: 8922199. DOI: 10.1001/jama.2022.2832. View

16.

van de Veerdonk F, Giamarellos-Bourboulis E, Pickkers P, Derde L, Leavis H, van Crevel R . A guide to immunotherapy for COVID-19. Nat Med. 2022; 28(1):39-50. DOI: 10.1038/s41591-021-01643-9. View

17.

Garneau W, Jones-Beatty K, Ufua M, Mostafa H, Klein S, Burd I . Analysis of Clinical Outcomes of Pregnant Patients Treated With Nirmatrelvir and Ritonavir for Acute SARS-CoV-2 Infection. JAMA Netw Open. 2022; 5(11):e2244141. PMC: 9709643. DOI: 10.1001/jamanetworkopen.2022.44141. View

18.

Potter G, Bonnett T, Rubenstein K, Lindholm D, Rapaka R, Doernberg S . Temporal Improvements in COVID-19 Outcomes for Hospitalized Adults: A Post Hoc Observational Study of Remdesivir Group Participants in the Adaptive COVID-19 Treatment Trial. Ann Intern Med. 2022; 175(12):1716-1727. PMC: 9709721. DOI: 10.7326/M22-2116. View

19.

Lim J, Park S, Jeon Y, Chung Y, Kwon J, Jeon Y . Clinical Effectiveness and Safety of Remdesivir in Hemodialysis Patients with COVID-19. Kidney Int Rep. 2022; 7(11):2522-2525. PMC: 9462925. DOI: 10.1016/j.ekir.2022.08.031. View

20.

Larsen C . Assessing the proportion of the Danish population at risk of clinically significant drug-drug interactions with new oral antivirals for early treatment of COVID-19. Int J Infect Dis. 2022; 122:599-601. PMC: 9258411. DOI: 10.1016/j.ijid.2022.06.059. View